PHRX — Pharmadrug Income Statement
0.000.00%
Last trade - 00:00- CA$1.08m
- CA$2.69m
Annual income statement for Pharmadrug, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.007 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | -0.002 | -0.002 | 0 | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2.8 | 2.41 | 14 | 0.705 | 0.108 |
| Operating Profit | -2.8 | -2.41 | -14 | -0.705 | -0.108 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4.28 | -3.25 | -14.3 | -0.873 | -0.433 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.28 | -3.06 | -13.3 | -0.873 | -0.433 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -5.63 | -8.88 | -13.2 | -0.793 | -0.383 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.63 | -8.88 | -13.2 | -0.793 | -0.383 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.085 | -0.061 | -0.09 | -0.007 | -0.005 |